PRQR boasts a pipeline of 18 drug candidates, nearly all in early-stage development.
Cash runway to last through to 2021 following recent public offering.
First half of 2019 catalysts: Phase II/III ILLUMINATE trial, Phase I/II STELLAR trial with interim results mid 2019, Phase I/II adRP clinical trial, WINGS interim data.
Share price jumps off positive news. With a pipeline of catalysts coming up in the next 3 months,du share price is poised to take off.